InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
InMed Pharmaceuticals Inc. reported a first-quarter fiscal 2027 net loss of $2,330,778 for the three months ended September 30, 2026, versus $1,726,899 for the three months ended September 30, 2025. Cash and cash equivalents were $1,094,488 at September 30, 2026, versus $2,194,413 at June 30, 2026. Research and development expenses were $206,015 versus $575,458; general and administrative expenses were $1,804,625 versus $1,239,058.
InMed expects available cash to fund planned operating expenses and capital expenditures into mid-November, depending on spending and the timing of the proposed merger with Mentari Therapeutics. The merger is expected to close in the fourth quarter of 2026, subject to remaining conditions including shareholder approvals; a shareholder meeting is scheduled for November 4, 2026. Mentari announced related private placements with approximately US$490 million in expected aggregate gross proceeds. Nasdaq accepted InMed's compliance plan and determined that InMed has until March 15, 2027, to regain compliance with the $2.5 million minimum shareholders' equity requirement; InMed reported negative shareholders' equity of $1,199,396 at September 30, 2026.
InMed Pharmaceuticals Inc. (INM) reported a $2.33 million net loss for the three months ended September 30, 2026, versus $1.73 million a year earlier. Continuing-operations loss was $2.00 million; operating cash use was $1.14 million, versus $1.93 million. At quarter-end, cash and cash equivalents were $1.09 million, short-term investments $40,331, and shareholders’ equity a $1.20 million deficit. BayMedica had wound down InMed’s only revenue-generating commercial operations.
Management concluded substantial doubt exists about InMed’s ability to continue as a going concern within one year after the statements’ issuance. It expects $1.1 million of cash, cash equivalents and short-term investments as of September 30, 2026, to fund operating expenses and capital expenditures into calendar Q4 2026, depending on spending levels and timing.
The proposed merger with Mentari is expected to close in Q4 2026, subject to conditions including shareholder approvals and Mentari’s pre-closing financing. The financing commitment is approximately $490.0 million, including $50.0 million previously received. Assuming InMed net cash of approximately $(4.4) million at closing, Mentari holders and pre-merger InMed securityholders are expected to own 99.03% and 0.97%, respectively, of the combined company on a fully diluted basis, subject to adjustment. Nasdaq notified InMed that equity of $1,075,007 reported in its 2026 Annual Report was below the $2.5 million minimum; InMed submitted a plan.
InMed Pharmaceuticals Inc. expects to consolidate its issued and outstanding Common Shares on a 1-for-10 basis, with one post-consolidation share for each 10 pre-consolidation shares. If completed, the count would fall from 5,493,735 to approximately 549,374 Common Shares on a non-diluted basis, before giving effect to the proposed merger with Mentari Therapeutics, Inc.; each shareholder would retain the same percentage ownership.
InMed will proceed only if its shareholders approve Proposals No. 1, 2 and 3 at the annual general and special meeting scheduled for November 4, 2026. It anticipates completing the consolidation after market close that day, with adjusted trading expected to begin at market open on November 5, 2026. The share counts and exercise prices of outstanding options, warrants and other convertible securities would be proportionately adjusted. Fractional shares would be rounded to the nearest whole share, with no cash or other consideration paid for rounding.
InMed Pharmaceuticals Inc.’s board fixed November 5, 2026, at close of business Eastern Time, as the record date for distributing InMed CVRs. Only holders of record of InMed Common Shares on that date will receive CVRs, which will be issued on the Closing Date. Because shares settle on a T+1 basis, people acquiring shares on or after the record date generally will not qualify. Shares issued after that date, including in the merger or upon surrender of In-the-Money InMed Options, will not receive CVRs. Shareholders who already voted do not need to vote again unless they wish to change their vote.
InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC purchased 4 common shares at $1.32 per share on October 23, 2026. The reported post-transaction position was 956,584 shares. The funds hold the securities directly; ADAR1, a ten-percent owner, and Daniel Schneeberger, a ten-percent owner and the LLC’s sole manager, may be deemed indirect beneficial owners. No Rule 10b5-1 plan is reported for the purchase.
InMed Pharmaceuticals Inc. announced that close of business on November 5, 2026 is the record date for a proposed distribution of contingent value rights (CVRs) connected with its proposed merger involving Mentari Therapeutics, Inc. If distributed, InMed would issue one CVR for each outstanding common share held on the record date; each CVR represents a right to contingent payments upon specified events under the CVR agreement.
The distribution is conditional on InMed shareholder approval of the Return of Capital Proposal at the annual general and special meeting scheduled for November 4, 2026. Investors who purchase common shares on November 5 are not expected to be holders of record on the CVR Distribution Record Date. Common shares issued upon surrender of InMed’s outstanding in-the-money stock options will not carry a corresponding CVR entitlement.
InMed Pharmaceuticals Inc. (INM) reports that private investment funds managed by ADAR1 Capital Management, LLC purchased 1,086 common shares on October 19, 2026, and 1 common share on October 16, 2026, each at $1.32 per share. The shares may be deemed indirectly beneficially owned by ADAR1 and Daniel Schneeberger, ADAR1’s sole manager. No Rule 10b5-1 plan is reported.
InMed Pharmaceuticals Inc. (INM) reports that private investment funds managed by ADAR1 Capital Management, LLC purchased 564 shares at $1.3300 on October 13, 2026; 8,021 at $1.3300 on October 14, 2026; and 984 at a $1.3219 weighted average on October 15, 2026. The October 15 purchases ranged from $1.3200 to $1.3300, inclusive. The funds’ shares may be deemed indirectly beneficially owned by ADAR1 Capital Management and Daniel Schneeberger, its sole manager; both are listed as ten-percent owners and disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.
InMed Pharmaceuticals Inc. (INM) reports that private investment funds managed by ADAR1 Capital Management, LLC purchased 10,903 common shares across October 6–8, 2026. The funds purchased 5,601 shares at a weighted average price of $1.3277 on October 6, 3,046 shares at $1.3300 on October 7, and 2,256 shares at a weighted average price of $1.3283 on October 8. No Rule 10b5-1 plan is reported.
The shares are owned directly by the funds and may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager; both are identified as ten percent owners. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
For InMed Pharmaceuticals, Inc., an amended beneficial-ownership report by ADAR1 Capital Management, LLC and Daniel Schneeberger states that private investment funds managed by ADAR1 directly own 943,668 common shares; those shares may be deemed indirectly beneficially owned by ADAR1 and its sole manager, Daniel Schneeberger. Both reporting persons reported shared voting and dispositive power over the position, with no sole voting or dispositive power. The reported ownership percentage is 17.2%, based on 5,493,735 common shares outstanding as of September 2, 2026.